Jay V. Vadgama

Jaydutt V. Vadgama, PhD

Professor, David Geffen School of Medicine at UCLA
Professor of Medicine, Charles Drew University of Medicine and Science
Chief, Division of Cancer Research and Training, Charles Drew University of Medicine and Science
Endowed Chair in Cancer Research, Charles Drew University of Medicine and Science
Director, Center to Eliminate Cancer Health Disparities, Department of Internal Medicine, Charles Drew University of Medicine and Science



Scientific Interests

Dr. Jay Vadgama has extensive experience in conducting oncology research that integrates clinical, basic and community-based studies. The outcome of these efforts has resulted in the development of translational cancer research at Charles Drew University (CDU). Research programs in his division focus on:

  1. genetics and epigenetics of breast, colorectal and prostate cancers
  2. identification of cellular and molecular markers and novel genes for early detection, prevention and management of breast, colorectal cancer and prostate cancers
  3. mechanisms associated with bone metastasis from breast cancer
  4. role of mismatch repair proteins and microsatellite instability in colorectal cancer in minority populations
  5. identification and characterization of normal and cancer stem cells in breast and prostate cancers that contribute to drug resistance
  6. cancer outreach and prevention studies.

Vadgama has developed an extensive tissue repository program with detailed clinical follow-up data on African American and Latina populations. He is principal investigator of several center grants in cancer at CDU in partnership with UCLA.

Highlighted Publications

Sarkissyan M, Wu Y, Vadgama JV. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer. 2011 Aug 15;117(16):3814-23. Epub 2011 Feb 8

Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM, Koeffler HP. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 2011 Jun;38(6):1741-7. Epub 2011 Mar 23

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 1;70(13):5475-85. Epub 2010 Jun 15

Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther. 2010 Jan;9(1):33-45. Epub 2010 Jan 6

Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 2008 Jan 10;10(1):R3. Epub 2008 Jan 10